Literature DB >> 15467468

Oncogenic mutations of PIK3CA in human cancers.

Yardena Samuels1, Victor E Velculescu.   

Abstract

Phosphatidylinositol 3-kinases (PI3Ks) are important regulators of signaling pathways. To determine whether PI3Ks are genetically altered in human cancers, we recently analyzed the sequences of the PI3K gene family and discovered that one member, the PIK3CA gene encoding the p110alpha catalytic subunit, was frequently mutated in cancers of the colon, breast, brain and lung. The majority of mutations clustered near two positions within the PI3K helical or catalytic domains and at least one hotspot mutation appeared to increase kinase activity. PIK3CA represents one of the most highly mutated oncogenes identified in human cancers and may be a useful diagnostic and therapeutic target.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15467468     DOI: 10.4161/cc.3.10.1164

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  179 in total

1.  Non-small cell lung carcinoma therapy using mTOR-siRNA.

Authors:  Hirochika Matsubara; Kenji Sakakibara; Tamo Kunimitsu; Hiroyasu Matsuoka; Kaori Kato; Noboru Oyachi; Yoh Dobashi; Masahiko Matsumoto
Journal:  Int J Clin Exp Pathol       Date:  2012-02-12

2.  FOXO3a and β-catenin co-localization: double trouble in colon cancer?

Authors:  Yibing Yan; Mark R Lackner
Journal:  Nat Med       Date:  2012-06-06       Impact factor: 53.440

Review 3.  Emerging role of the KRAS-PDK1 axis in pancreatic cancer.

Authors:  Riccardo Ferro; Marco Falasca
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

4.  Measurement of constitutive MAPK and PI3K/AKT signaling activity in human cancer cell lines.

Authors:  Kim H T Paraiso; Kaisa Van Der Kooi; Jane L Messina; Keiran S M Smalley
Journal:  Methods Enzymol       Date:  2010       Impact factor: 1.600

5.  Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma.

Authors:  Martina Rudelius; Stefania Pittaluga; Satoshi Nishizuka; Trinh H-T Pham; Falko Fend; Elaine S Jaffe; Leticia Quintanilla-Martinez; Mark Raffeld
Journal:  Blood       Date:  2006-04-27       Impact factor: 22.113

6.  Activating BRAF and PIK3CA mutations cooperate to promote anaplastic thyroid carcinogenesis.

Authors:  Roch-Philippe Charles; Jillian Silva; Gioia Iezza; Wayne A Phillips; Martin McMahon
Journal:  Mol Cancer Res       Date:  2014-04-25       Impact factor: 5.852

7.  Novel mutant-enriched sequencing identified high frequency of PIK3CA mutations in pharyngeal cancer.

Authors:  Wanglong Qiu; Guo-Xia Tong; Spiros Manolidis; Lanny G Close; Adel M Assaad; Gloria H Su
Journal:  Int J Cancer       Date:  2008-03-01       Impact factor: 7.396

8.  Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations.

Authors:  Prasanth Ganesan; Filip Janku; Aung Naing; David S Hong; Apostolia M Tsimberidou; Gerald S Falchook; Jennifer J Wheler; Sarina A Piha-Paul; Siqing Fu; Vanda M Stepanek; J Jack Lee; Rajyalakshmi Luthra; Michael J Overman; E Scott Kopetz; Robert A Wolff; Razelle Kurzrock
Journal:  Mol Cancer Ther       Date:  2013-10-03       Impact factor: 6.261

Review 9.  Targeting the PI3K signaling pathway in cancer.

Authors:  Kwok-Kin Wong; Jeffrey A Engelman; Lewis C Cantley
Journal:  Curr Opin Genet Dev       Date:  2009-12-16       Impact factor: 5.578

Review 10.  The PI3K pathway as drug target in human cancer.

Authors:  Kevin D Courtney; Ryan B Corcoran; Jeffrey A Engelman
Journal:  J Clin Oncol       Date:  2010-01-19       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.